Abstract Body

Background

The adjuvanted recombinant zoster vaccine (RZV), based on varicella glycoprotein E (gE) and licensed in 2017, prevents herpes zoster (HZ) and induces durable humoral responses in people without HIV (typically >10 years). The incidence of HZ is higher among PWH, yet data on vaccine response and durability remain limited. We evaluated humoral immune responses to RZV using samples from the U.S. Military HIV Natural History Study.

Methods

Participants with paired serum samples collected before (baseline) and after RZV (1–12 months post–dose 2) were included. Anti-gE antibody (Ab) concentrations were measured using a quantitative enzyme-linked immunosorbent assay. Vaccine response was defined as a ≥4-fold increase from baseline. Durability was assessed in participants with samples 3–5 years post-vaccination. Antibody levels are reported as geometric mean concentrations (GMC) with 95% confidence intervals (CI), and fold changes as geometric mean fold rise (GMFR). Continuous variables are expressed as medians with 25th and 75th percentiles. Group comparisons used Kruskal–Wallis and Fisher’s exact tests.

Results

At baseline, all participants (n=63; median age 60; 83% male; median CD4 645 [483–859]; 89% suppressed) were anti-gE Ab positive. After vaccination, 87% responded, and responses persisted in 73% (33/45) at 3–5 years. Compared with non-responders, at baseline responders had higher CD4 counts (687 [487–873] vs 525 [105–640], p=0.058), higher nadir CD4 counts (213 [100–304] vs 81 [24–152], p=0.05), greater ART use (98% vs 75%, p=0.04), were more often virologically suppressed (93% vs 63%, p=0.04), and lower baseline anti-gE Ab levels (7479 [5283–10589] vs 29568 [10427–83848], p=0.003). Pre-vaccination GMC was 8906 (6294–12601). Antibody levels increased 22-fold after dose 2 and remained 8-fold above baseline at 3–5 years. Participants with CD4 <350 had significantly lower GMFR after dose 2 (5.9-fold vs 28.1-fold, p=0.002) and reduced durability (2.2-fold vs 11.3-fold, p=0.006) compared with those with CD4 ≥350.

Conclusions

Despite virologic suppression, in a majority, 1 in 4 PWH failed to sustain humoral responses 5 years after RZV. Lower pre-vaccination CD4 counts were associated with both non-response and reduced durability. As humoral immunity may not equate to clinical protection, further study is needed to determine the clinical significance of these findings and whether booster doses should be considered for PWH with low pre-vaccination CD4 counts.

Table or Figure